Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMZJUV6)

Drug Name	CSJ117 DMZJUV6
Synonyms	Ecleralimab
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Chronic obstructive pulmonary disease	DISQCIRF	CA22	Phase 2	[1]
Asthma	DISW9QNS	CA23	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04882124) A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04410523) A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients >= 18 Years of Age With Severe Uncontrolled Asthma. U.S.National Institutes of Health.